Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announces the enrollment of the first patient in RE-COVERY DVT/PE™, a global observational study on the management of blood clots in the legs (deep vein thrombosis, DVT) and in the lungs (pulmonary embolism, PE).
Bristol-Myers Squibb to acquire Padlock Therapeutics, Inc.
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Padlock Therapeutics, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases.
AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke
- Details
- Category: AstraZeneca
AstraZeneca today announced the top-line results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA).
Amgen and UCB announce positive top-line tesults from phase 3 study evaluating romosozumab In men with osteoporosis
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced positive top-line results for romosozumab from the pivotal Phase 3 placeBo-contRolled study evaluatIng the efficacy anD safety of romosozumab in treatinG mEn with osteoporosis (BRIDGE).
Abbott's Absorb, the first fully dissolving heart stent, earns positive review by FDA advisory committee
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced that an independent panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 9 to 0, with one abstention, that the benefits of Abbott's Absorb fully bioresorbable drug eluting coronary stent outweigh the risks.
Pfizer celebrates a year of achievements in 2015 annual review
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has released its 2015 integrated annual review, an in-depth look into the company's financial, social and environmental performance. 2015 was marked by breakthrough scientific research, collaborations and partnerships.
FDA grants Roche's Cancer Immunotherapy Atezolizumab priority review for advanced bladder cancer
- Details
- Category: Roche
Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and granted Priority Review for atezolizumab (anti-PDL1; MPDL3280A) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC)
More Pharma News ...
- Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial
- Pfizer commences $5 billion accelerated share repurchase
- AstraZeneca's potential medicine for neuromyelitis optica receives FDA Orphan Drug Designation
- Sanofi Pasteur and MSD announce intent to end joint vaccines operations in Europe
- GSK names winners of 2015 Discovery Fast Track Challenge
- Bristol-Myers Squibb and LabCentral team up in Cambridge, Massachusetts to support promising biotech startup companies
- Merck, Pfizer and Verastem announce combination trial of avelumab and VS-6063 in ovarian cancer